(UroToday.com) First-line pembrolizumab monotherapy, although not standard of care, has demonstrated efficacy in clear cell renal cell carcinoma (RCC). Previously, the first-line KEYNOTE-427 study demonstrated an overall response rate of 34%, and a median progression-free survival of 7.1 months. Stereotactic ablative body radiotherapy is an option for oligometastatic clear cell RCC, but patients often develop distant progression or relapse within irradiated sites. During the Renal Cell Cancer Rapid Abstract Session at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Shankar Siva and colleagues presented results of the RAPPORT study (NCT02855203), a multi-institutional, single-arm, Phase I/II study evaluating safety and efficacy of stereotactic ablative body radiotherapy and pembrolizumab.